DDInter695 DDInter1652
An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). It is currently approved to treat a number of chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.[L39600,L42280,L48771]
Ethosuximide {u} (Compound) resembles {v} (Compound) Methyprylon
Ethosuximide {u} (Compound) binds {v} (Gene) CYP3A7-CYP3A51P
Ethosuximide {u} (Compound) upregulates {v} (Gene) ZNF586
Ethosuximide {u} (Compound) is included by {v} (Pharmacologic Class) Decreased Central Nervous System Disorganized Electrical Activity
Ethosuximide {u} (Compound) downregulates {v} (Gene) BAG3
Ethosuximide {u} (Compound) causes {v} (Side Effect) Malnutrition
Ethosuximide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Promethazine
Ethosuximide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nabilone
Ethosuximide (Compound) resembles Methyprylon (Compound)
Ethosuximide (Compound) binds CYP3A7-CYP3A51P (Gene)
Ethosuximide (Compound) upregulates ZNF586 (Gene)
Ethosuximide (Compound) is included by Decreased Central Nervous System Disorganized Electrical Activity (Pharmacologic Class)
Ethosuximide (Compound) downregulates BAG3 (Gene)
Ethosuximide (Compound) causes Malnutrition (Side Effect)
Ethosuximide may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Ethosuximide may cause a moderate interaction that could exacerbate diseases when taken with Nabilone